4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Eighteenth informational supplement. CIGI documents M100-S18. CLSI/NCCLS,2008.
5Granger D, Boily-Larouche G, Turgeon P, et al. Molecular characteristics of pbpla and pbp2b in clinical Streptococcus pneurnoniae isolates in Quebec. Canada[J]. J Antimierob Chemoter,2006,57(1):61-70.
6Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamases-producing Enterobacteriaeeae[J]. Antimierob Agents Chemother, 2006,50(4) : 1257-1262.
7Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-β-lactamases-producing Klebsiella pneumoniae :risk factors, molecular epidemiol- ogy and clinical outcome[J]. Antimicrob Agents Chemother, 2006,50(2):498 504.
8Wang H, Kelkar S, Wu WY, etal. Clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamases:prevalence of CTX-M 3 at a hospital in China[J]. Antimicrob Agents Chemother, 2003,47(2) : 790-793.
9Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically[S]. Seventh edition. Approved Standard. CLSI documents M7 A7. CLSI,2006.
10Fabbro-Peray P , Sotto A, Defez C, et al . Mortality attributa-ble to healthcare-associated infection: acohort of patients withand without healthcare-associated infection in a French univer-sity hospital[J]. J Control Hosp Epidemiol,2007,28 : 265-272.
